<code id='EE54815410'></code><style id='EE54815410'></style>
    • <acronym id='EE54815410'></acronym>
      <center id='EE54815410'><center id='EE54815410'><tfoot id='EE54815410'></tfoot></center><abbr id='EE54815410'><dir id='EE54815410'><tfoot id='EE54815410'></tfoot><noframes id='EE54815410'>

    • <optgroup id='EE54815410'><strike id='EE54815410'><sup id='EE54815410'></sup></strike><code id='EE54815410'></code></optgroup>
        1. <b id='EE54815410'><label id='EE54815410'><select id='EE54815410'><dt id='EE54815410'><span id='EE54815410'></span></dt></select></label></b><u id='EE54815410'></u>
          <i id='EE54815410'><strike id='EE54815410'><tt id='EE54815410'><pre id='EE54815410'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:explore    Page View:53
          FDA stop sign
          Sarah Silbiger/Getty Images

          The Food and Drug Administration is cracking down on websites that claim to sell the underlying chemicals of popular diabetes and obesity drugs like Ozempic, Wegovy, and Zepbound, saying that the websites are selling unapproved and misbranded drug products.

          The regulator this week posted warning letters that it sent to two websites, Synthetix Inc. DBA Helix Chemical Supply and US Chem Labs. Though those websites say their chemicals are “for research use” and “not for human consumption,” the FDA said it found evidence on their pages showing that their products are indeed intended for human use, such as information about dosing and claims about the clinical benefits of the products.

          advertisement

          The two websites did not immediately respond to requests for comment. The FDA said they have 15 working days to respond and detail the steps they’ve taken to address any violations.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          5 to watch: Tech startups trying to solve health care's staffing crisis
          5 to watch: Tech startups trying to solve health care's staffing crisis

          AdobeThreeyearsafterthepandemicupendedthehealthcareworkforce,hospitalstaffingisstillatopconcernforho

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Readout Newsletter: Bluebird, CVS, Contineum

          JustinSullivan/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetour